GlassScriptPhysician profile
Michele M Wooten
NPI 1114299468
$8,407.95
in general payments reported to CMS, 2019-2025
55 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,263 · 2022: $1,275 · 2023: $2,507 · 2024: $1,912 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,805 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,805.12 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,273.23 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $762.72 | 2021-2025 | |
| Lilly USA, LLC | $740.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $675.62 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $670.62 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $341.60 | 2021-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $336.15 | 2021-2025 | |
| Glaxosmithkline, LLC. | $313.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $248.32 | 2021-2025 | |
| Amgen INC. | $237.28 | 2021-2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $235.23 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $230.49 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $210.50 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.25 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $152.26 | 2021-2023 | Verquvo, Belsomra |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Wooten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.